Selected article for: "clinical severity and expression level"
Author: Chin-Yi Chu; Xing Qiu; Matthew N. McCall; Lu Wang; Anthony Corbett; Jeanne Holden-Wiltse; Christopher Slaunwhite; Qian Wang; Christopher Anderson; Alex Grier; Steven R. Gill; Gloria S. Pryhuber; Ann R. Falsey; David J. Topham; Mary T. Caserta; Edward E. Walsh; Thomas J Mariani
Title: Insufficiency in airway interferon activation defines clinical severity to infant RSV infection
  • Document date: 2019_5_20
    • ID: bx49tbui_94
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/641795 doi: bioRxiv preprint prior studies focusing on severely affected infants, as compared to non-infected infants, as they both show limited evidence for activation of this pathway. In this way, our studies, focused upon clinical severity in a cohort where all were infected with RSV, provides opportunity for different insights......
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/641795 doi: bioRxiv preprint prior studies focusing on severely affected infants, as compared to non-infected infants, as they both show limited evidence for activation of this pathway. In this way, our studies, focused upon clinical severity in a cohort where all were infected with RSV, provides opportunity for different insights. We also draw attention to the narrow time window in which differences in IFN between these groups is evident (Fig. 4) . Even in our own data, differences in expression do not reach the level of statistical significance without restricting our analyses to the first few days following the onset of clinical symptoms.

    Search related documents:
    Co phrase search for related documents
    • attention draw and limited evidence: 1, 2
    • clinical severity and different insight: 1, 2
    • clinical severity and expression difference: 1, 2
    • clinical severity and IFN difference: 1
    • clinical severity and limited evidence: 1, 2, 3, 4, 5, 6, 7
    • clinical severity and opportunity provide: 1, 2, 3, 4
    • clinical severity and pathway activation: 1, 2, 3, 4
    • clinical symptom and limited evidence: 1, 2
    • clinical symptom and opportunity provide: 1
    • clinical symptom onset and limited evidence: 1
    • clinical symptom onset and opportunity provide: 1
    • expression difference and IFN difference: 1, 2, 3, 4, 5, 6
    • expression difference and pathway activation: 1
    • limited evidence and opportunity provide: 1
    • opportunity provide and pathway activation: 1, 2